These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 15544557)

  • 1. Medicinal chemical and pharmacological aspects of imidazole-containing histamine H3 receptor antagonists.
    Stark H; Kathmann M; Schlicker E; Schunack W; Schlegel B; Sippl W
    Mini Rev Med Chem; 2004 Nov; 4(9):965-77. PubMed ID: 15544557
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Medicinal chemistry and biological properties of non-imidazole histamine H3 antagonists.
    Cowart M; Altenbach R; Black L; Faghih R; Zhao C; Hancock AA
    Mini Rev Med Chem; 2004 Nov; 4(9):979-92. PubMed ID: 15544558
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro characterization of potency, affinity and selectivity of H3-antagonists: from thioperamide to thioperamide unrelated imidazole derivatives.
    Barocelli E; Ballabeni V; Caretta A; Bertoni S; Bordi F; Rivara S; Silva C; Mor M; Impicciatore M
    Farmaco; 1997; 52(6-7):463-9. PubMed ID: 9372599
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 3: 5-Substituted 3-phenyl-1,2,4-oxadiazoles as potent antagonists.
    Gfesser GA; Zhang H; Dinges J; Fox GB; Pan JB; Esbenshade TA; Yao BB; Witte D; Miller TR; Kang CH; Krueger KM; Bennani YL; Hancock AA; Faghih R
    Bioorg Med Chem Lett; 2004 Feb; 14(3):673-6. PubMed ID: 14741266
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 2-(4-alkylpiperazin-1-yl)quinolines as a new class of imidazole-free histamine H3 receptor antagonists.
    Zaragoza F; Stephensen H; Peschke B; Rimvall K
    J Med Chem; 2005 Jan; 48(1):306-11. PubMed ID: 15634025
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structural variations of 1-(4-(phenoxymethyl)benzyl)piperidines as nonimidazole histamine H3 receptor antagonists.
    Mikó T; Ligneau X; Pertz HH; Arrang JM; Ganellin CR; Schwartz JC; Schunack W; Stark H
    Bioorg Med Chem; 2004 May; 12(10):2727-36. PubMed ID: 15110854
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Replacement of imidazole by a piperidine moiety differentially affects the potency of histamine H3-receptor antagonists.
    Liedtke S; Flau K; Kathmann M; Schlicker E; Stark H; Meier G; Schunack W
    Naunyn Schmiedebergs Arch Pharmacol; 2003 Jan; 367(1):43-50. PubMed ID: 12616340
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design and synthesis of histamine H
    Watanabe M; Kobayashi T; Ito Y; Fukuda H; Yamada S; Arisawa M; Shuto S
    Bioorg Med Chem Lett; 2018 Dec; 28(23-24):3630-3633. PubMed ID: 30385161
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and histamine H3 receptor activity of 4-(n-alkyl)-1H-imidazoles and 4-(omega-phenylalkyl)-1H-imidazoles.
    De Esch IJ; Gaffar A; Menge WM; Timmerman H
    Bioorg Med Chem; 1999 Dec; 7(12):3003-9. PubMed ID: 10658607
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 4-[(1H-imidazol-4-yl) methyl] benzamidines and benzylamidines: novel antagonists of the histamine H3 receptor.
    Aslanian R; Brown JE; Shih NY; wa Mutahi M; Green MJ; She S; Del Prado M; West R; Hey J
    Bioorg Med Chem Lett; 1998 Aug; 8(16):2263-8. PubMed ID: 9873525
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification and pharmacological characterization of a series of new 1H-4-substituted-imidazoyl histamine H3 receptor ligands.
    Yates SL; Phillips JG; Gregory R; Pawlowski GP; Fadnis L; Khan MA; Ali SM; Tedford CE
    J Pharmacol Exp Ther; 1999 May; 289(2):1151-9. PubMed ID: 10215699
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacological characterization of H3 receptor antagonists with imidazole, thioimidazole and thioimidazoline polar groups in the side chain.
    Barocelli E; Ballabeni V; Chiavarini M; Bertoni S; Mor M; Plazzi PV; Bordi F; Impicciatore M
    Inflamm Res; 2000 Apr; 49 Suppl 1():S62-3. PubMed ID: 10864424
    [No Abstract]   [Full Text] [Related]  

  • 13. Structure-activity relationships of new 1-substitutedmethyl-4-[5-(N-methyl-N-propylamino)pentyloxy]piperidines and selected 1-[(N-substituted-N-methyl)-3-propyloxy]-5-(N-methy-l-N-propyl)-pentanediamines as H3 -antagonists.
    Masłowska-Lipowicz I; Walczyński K
    Chem Biol Drug Des; 2014 Jan; 83(1):106-18. PubMed ID: 23957330
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and three-dimensional quantitative structure-activity relationship analysis of H3 receptor antagonists containing a neutral heterocyclic polar group.
    Rivara S; Mor M; Bordi F; Silva C; Zuliani V; Vacondio F; Morini G; Plazzi PV; Carrupt PA; Testa B
    Drug Des Discov; 2003; 18(2-3):65-79. PubMed ID: 14675944
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel histamine H(3)-receptor antagonists with carbonyl-substituted 4-(3-(phenoxy)propyl)-1H-imidazole structures like ciproxifan and related compounds.
    Stark H; Sadek B; Krause M; Hüls A; Ligneau X; Ganellin CR; Arrang JM; Schwartz JC; Schunack W
    J Med Chem; 2000 Oct; 43(21):3987-94. PubMed ID: 11052804
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lack of cataleptogenic potentiation with non-imidazole H3 receptor antagonists reveals potential drug-drug interactions between imidazole-based H3 receptor antagonists and antipsychotic drugs.
    Zhang M; Ballard ME; Pan L; Roberts S; Faghih R; Cowart M; Esbenshade TA; Fox GB; Decker MW; Hancock AA; Rueter LE
    Brain Res; 2005 May; 1045(1-2):142-9. PubMed ID: 15910772
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of a pharmacophore model for histamine H3 receptor antagonists, using the newly developed molecular modeling program SLATE.
    De Esch IJ; Mills JE; Perkins TD; Romeo G; Hoffmann M; Wieland K; Leurs R; Menge WM; Nederkoorn PH; Dean PM; Timmerman H
    J Med Chem; 2001 May; 44(11):1666-74. PubMed ID: 11356102
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A qualitative model for the histamine H3 receptor explaining agonistic and antagonistic activity simultaneously.
    de Esch IJ; Timmerman H; Menge WM; Nederkoorn PH
    Arch Pharm (Weinheim); 2000 Aug; 333(8):254-60. PubMed ID: 11008375
    [TBL] [Abstract][Full Text] [Related]  

  • 19. N-Alkenyl and cycloalkyl carbamates as dual acting histamine H3 and H4 receptor ligands.
    Więcek M; Kottke T; Ligneau X; Schunack W; Seifert R; Stark H; Handzlik J; Kieć-Kononowicz K
    Bioorg Med Chem; 2011 May; 19(9):2850-8. PubMed ID: 21498080
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acidic elements in histamine H(3) receptor antagonists.
    Sander K; von Coburg Y; Camelin JC; Ligneau X; Rau O; Schubert-Zsilavecz M; Schwartz JC; Stark H
    Bioorg Med Chem Lett; 2010 Mar; 20(5):1581-4. PubMed ID: 20138762
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.